Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...
Bristol-Myers Squibb's flurry of dealmaking has continued with en expansion of its partnership with BridgeBio on drugs targeting SHP2, in the hope of combining them with its cancer immunotherapy ...
The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.
Key market opportunities for liraglutide and semaglutide include their growing role in diabetes and obesity treatment due to ...
From mobile jobs to nature photography, BLUETTI aims at all profiles. The fast charging of Canon, DJI, or Apple batteries ensures the success of photo shoots away from the grid. The station thus ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback